Phase 2 N=22 Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Objective Response Rate — 1; 7; 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=178 Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma · Recurrent Osteosarcoma
Primary: Progression-free Survival Rate, Defined as CR + PR + SD, as Assessed by RECIST Criteria — 4; 57; 98 participants
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 2 N=53 Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants
Phase 2 N=30 Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Clinical Response — 0; 3; 7; 19 Participants
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=63 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Fallopian Tube Cancer · Female Reproductive Cancer · Ovarian Carcinosarcoma
Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants
Phase 2 N=14 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Adult Synovial Sarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants
Phase 1 N=26 A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma
Soft-tissue Sarcoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 1 Participants
Phase 2 N=111 A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Advanced Soft Tissue Sarcoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 3; 1; 22 Participants
N/A N=23 Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
Stage IIA Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo — -0.1; -0.1 Standardized uptake value-SUV — p=0.4
Phase 2 N=34 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Phase 2 N=8 Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Phase 2 N=55 Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Refractory Soft Tissue Sarcomas
Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants
Phase 2 N=70 Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Progression-free Survival — 1.8; 3.7 months